Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/12413/de%20la%20Rosette-Jean%20J.M.C.H-2024.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2024Author
Baard, JoyceCormio, Luigi
Dasgupta, Ranan
Maruzzi, Daniele
Rais-Bahrami, Soroush
Serrano, Alvaro
Geavlete, Bogdan
Giannakopoulos, Stilianos
de la Rosette, Jean J. M. C. H.
del Pilar Laguna Pes, Maria
Metadata
Show full item recordCitation
Baard, J., Cormio, L., Dasgupta, R., Maruzzi, D., Rais-Bahrami, S., Serrano, A. ... del Pilar Laguna Pes, M. (2024). Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study. World Journal of Urology, 42(1). https://dx.doi.org/10.1007/s00345-024-04866-wAbstract
Purpose: Diagnostic ureteroscopy (dURS) is optional in the assessment of patients with upper tract urothelial carcinoma (UTUC) and provides the possibility of obtaining histology. Methods: To evaluate endoscopic biopsy techniques and outcomes, we assessed data from patients from the CROES-UTUC registry. The registry includes multicenter prospective collected data on diagnosis and management of patients suspected having UTUC. Results: We assessed 2380 patients from 101 centers. dURS with biopsy was performed in 31.6% of patients. The quality of samples was sufficient for diagnosis in 83.5% of cases. There was no significant association between biopsy techniques and quality (p = 0.458). High-grade biopsy accurately predicted high-grade disease in 95.7% and high-risk stage disease in 86%. In ureteroscopic low-grade tumours, the prediction of subsequent low-grade disease was 66.9% and low-risk stage Ta-disease 35.8%. Ureteroscopic staging correctly predicted non-invasive Ta-disease and ≥ T1 disease in 48.9% and 47.9% of patients, respectively. Cytology outcomes did not provide additional value in predicting tumour grade. Conclusion: Biopsy results adequately predict high-grade and high-risk disease, but approximately one-third of patients are under-staged. Two-thirds of patients with low-grade URS-biopsy have high-risk stage disease, highlighting the need for improved diagnostics to better assess patient risk and guide treatment decisions. Clinical trial registration: The study was registered at ClinicalTrials.gov (ClinicalTrials.gov NCT02281188; https://clinicaltrials.gov/ct2/show/NCT02281188).
xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q1Source
World Journal of UrologyVolume
42Issue
1Collections
- Makale Koleksiyonu [3790]
- Makale Koleksiyonu [358]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]